T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.64% |
| 2 | Consumer Discretionary | 13.46% |
| 3 | Financials | 12.79% |
| 4 | Industrials | 12.13% |
| 5 | Technology | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
D.R. Horton
DHI
$42.1B
| $651M | 0.14% |
26,496,803
+1,765,093
| +7% | +$40.3M |
|
177
Marriott International
MAR
$90.9B
| $651M | 0.14% |
10,155,140
-4,710,415
| -32% | -$280M |
|
178
Mondelez International
MDLZ
$78.6B
| $649M | 0.14% |
17,265,142
+2,082,315
| +14% | +$76.1M |
|
179
Zoetis
ZTS
$30.9B
| $647M | 0.14% |
20,041,574
+6,953,363
| +53% | +$213M |
|
|
RDS.B
180
DELISTED
Royal Dutch Shell PLC ADS Class B
RDS.B
| $646M | 0.14% |
7,424,290
+118,632
| +2% | +$9.86M |
|
|
CFN
181
DELISTED
CAREFUSION CORPORATION
CFN
| $639M | 0.14% |
14,415,868
+4,045,650
| +39% | +$167M |
|
182
Xylem
XYL
$28.7B
| $637M | 0.14% |
16,307,058
+3,582,722
| +28% | +$134M |
|
|
STI
183
DELISTED
SunTrust Banks, Inc.
STI
| $634M | 0.14% |
15,817,256
-28,300
| -0.2% | -$1.1M |
|
|
VMW
184
DELISTED
VMware, Inc
VMW
| $629M | 0.14% |
6,500,932
+39,129
| +0.6% | +$3.8M |
|
|
PLL
185
DELISTED
PALL CORP
PLL
| $626M | 0.14% |
7,334,888
+140,626
| +2% | +$12M |
|
186
Gartner
IT
$11.8B
| $624M | 0.13% |
8,849,735
-868,076
| -9% | -$60.5M |
|
|
RAD
187
DELISTED
Rite Aid Corporation
RAD
| $622M | 0.13% |
4,340,521
+677,261
| +18% | +$100M |
|
188
IDEX
IEX
$17.5B
| $622M | 0.13% |
7,701,230
-96,500
| -1% | -$7.3M |
|
189
Motorola Solutions
MSI
$76.7B
| $615M | 0.13% |
9,239,328
+575,058
| +7% | +$37.8M |
|
190
VeriSign
VRSN
$26.3B
| $615M | 0.13% |
12,590,692
+2,014,586
| +19% | +$100M |
|
191
Factset
FDS
$10.1B
| $608M | 0.13% |
5,054,502
-545,800
| -10% | -$59.2M |
|
192
Coca-Cola
KO
$372B
| $604M | 0.13% |
14,255,646
-590,527
| -4% | -$24M |
|
193
Stratasys
SSYS
$775M
| $604M | 0.13% |
5,312,024
+4,587,553
| +633% | +$450M |
|
194
Cooper Companies
COO
$15B
| $603M | 0.13% |
17,788,488
-495,752
| -3% | -$16.4M |
|
|
AGN
195
DELISTED
Allergan plc
AGN
| $603M | 0.13% |
2,701,642
+133,507
| +5% | +$27.6M |
|
196
NXP Semiconductors
NXPI
$59B
| $592M | 0.13% |
8,952,218
-4,183,088
| -32% | -$256M |
|
197
Amgen
AMGN
$224B
| $591M | 0.13% |
4,989,139
-62,464
| -1% | -$7.23M |
|
|
CNQR
198
DELISTED
CONCUR TECHNOLOGIES INC
CNQR
| $590M | 0.13% |
6,325,768
-584,719
| -8% | -$51.2M |
|
199
Bath & Body Works
BBWI
$3.83B
| $584M | 0.13% |
12,309,368
-138,015
| -1% | -$6.32M |
|
200
Blackrock
BLK
$177B
| $579M | 0.13% |
1,811,661
+161,196
| +10% | +$49.4M |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.